Epidemiology of Alcohol-Associated Liver Disease

Overview

Journal Clin Liver Dis

Specialty Gastroenterology

Date 2021 Jul 7

PMID 34229835

Citations 13

Authors

Sen Han

Zhihong Yang

Ting Zhang

Jing Ma

Kristina Chandler

Suthat Liangpunsakul

Affiliations

Soon will be listed here.

Abstract

Alcohol-associated liver disease (ALD) is a consequence of excessive alcohol use. It comprises a spectrum of histopathologic changes ranging from simple steatosis, steatohepatitis, and cirrhosis to hepatocellular carcinoma. The public health impact of ALD is growing because of an increase in the prevalence and incidence of ALD in parallel with liver transplant and mortalities. There are multiple factors involved in the pathogenesis and progression of ALD. Reducing alcohol consumption is the cornerstone of ALD management. The efforts to reduce excessive alcohol use at the individual and population levels are urgently needed to prevent adverse outcomes from ALD.

Citing Articles

Silencing FAF2 mitigates alcohol-induced hepatic steatosis by modulating lipolysis and PCSK9 pathway.

Huda N, Kusumanchi P, Jiang Y, Gao H, Thoudam T, Zeng G Hepatol Commun. 2025; 9(3).

PMID: 39969435 PMC: 11841855. DOI: 10.1097/HC9.0000000000000641.

Prospective study on time-to-tertiary care in alcohol-associated hepatitis: space-time coordinates as prognostic tool and therapeutic target.

Skladany L, Zilincanova D, Kubanek N, Selcanova S, Havaj D, Laffers L Alcohol Alcohol. 2025; 60(2).

PMID: 39829300 PMC: 11744045. DOI: 10.1093/alcalc/agae092.

Advances in the management of alcohol-associated liver disease.

Anouti A, Kerr T, Mitchell M, Cotter T Gastroenterol Rep (Oxf). 2024; 12:goae097.

PMID: 39502523 PMC: 11537353. DOI: 10.1093/gastro/goae097.

Diagnosis of Alcohol Use Disorder and Alcohol-Associated Liver Disease.

Witkiewitz K, Fernandez A, Green E, Mellinger J Clin Liver Dis. 2024; 28(4):699-713.

PMID: 39362716 PMC: 11463730. DOI: 10.1016/j.cld.2024.06.009.

Novel medications for problematic alcohol use.

Heilig M, Witkiewitz K, Ray L, Leggio L J Clin Invest. 2024; 134(11).

PMID: 38828724 PMC: 11142745. DOI: 10.1172/JCI172889.

References

Sheth M, Riggs M, Patel T . Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol. 2002; 2:2. PMC: 65516. DOI: 10.1186/1471-230x-2-2. View

Lee B, Vittinghoff E, Dodge J, Cullaro G, Terrault N . National Trends and Long-term Outcomes of Liver Transplant for Alcohol-Associated Liver Disease in the United States. JAMA Intern Med. 2019; 179(3):340-348. PMC: 6439700. DOI: 10.1001/jamainternmed.2018.6536. View

Kamper-Jorgensen M, Gronbaek M, Tolstrup J, Becker U . Alcohol and cirrhosis: dose--response or threshold effect?. J Hepatol. 2004; 41(1):25-30. DOI: 10.1016/j.jhep.2004.03.002. View

Liangpunsakul S . Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States. J Clin Gastroenterol. 2010; 45(8):714-9. PMC: 3135756. DOI: 10.1097/MCG.0b013e3181fdef1d. View

Innes H, Morling J, Aspinall E, Goldberg D, Hutchinson S, Guha I . Late diagnosis of chronic liver disease in a community cohort (UK biobank): determinants and impact on subsequent survival. Public Health. 2020; 187:165-171. DOI: 10.1016/j.puhe.2020.07.017. View

Whitfield J, Masson S, Liangpunsakul S, Mueller S, Aithal G, Eyer F . Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers. Am J Gastroenterol. 2020; 116(1):106-115. DOI: 10.14309/ajg.0000000000000833. View

Adejumo A, Cholankeril G, Iqbal U, Yoo E, Boursiquot B, Concepcion W . Readmission Rates and Associated Outcomes for Alcoholic Hepatitis: A Nationwide Cohort Study. Dig Dis Sci. 2019; 65(4):990-1002. DOI: 10.1007/s10620-019-05759-4. View

Moreno C, Mueller S, Szabo G . Non-invasive diagnosis and biomarkers in alcohol-related liver disease. J Hepatol. 2019; 70(2):273-283. DOI: 10.1016/j.jhep.2018.11.025. View

Peng J, Patel M, McGee B, Liang T, Chandler K, Tayarachakul S . Management of alcohol misuse in patients with liver diseases. J Investig Med. 2016; 65(3):673-680. PMC: 5495189. DOI: 10.1136/jim-2016-000254. View

10.

Peeraphatdit T, Kamath P, Karpyak V, Davis B, Desai V, Liangpunsakul S . Alcohol Rehabilitation Within 30 Days of Hospital Discharge Is Associated With Reduced Readmission, Relapse, and Death in Patients With Alcoholic Hepatitis. Clin Gastroenterol Hepatol. 2019; 18(2):477-485.e5. PMC: 9764228. DOI: 10.1016/j.cgh.2019.04.048. View

11.

Younossi Z, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N . Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2019; 69(3):564-568. DOI: 10.1136/gutjnl-2019-318813. View

12.

Thursz M, Richardson P, Allison M, Austin A, Bowers M, Day C . Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015; 372(17):1619-28. DOI: 10.1056/NEJMoa1412278. View

13.

Elder R, Lawrence B, Ferguson A, Naimi T, Brewer R, Chattopadhyay S . The effectiveness of tax policy interventions for reducing excessive alcohol consumption and related harms. Am J Prev Med. 2010; 38(2):217-29. PMC: 3735171. DOI: 10.1016/j.amepre.2009.11.005. View

14.

Balakrishnan M, Pappas S . Alcohol and the Law. Clin Liver Dis. 2018; 23(1):25-38. DOI: 10.1016/j.cld.2018.09.002. View

15.

Ruhl C, Everhart J . Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol. 2005; 3(12):1260-8. DOI: 10.1016/s1542-3565(05)00743-3. View

16.

Liangpunsakul S, Beaudoin J, Shah V, Puri P, Sanyal A, Kamath P . Interaction between the patatin-like phospholipase domain-containing protein 3 genotype and coffee drinking and the risk for acute alcoholic hepatitis. Hepatol Commun. 2018; 2(1):29-34. PMC: 5776869. DOI: 10.1002/hep4.1123. View

17.

Mills S, Harrison S . Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease. Curr Gastroenterol Rep. 2005; 7(1):32-6. DOI: 10.1007/s11894-005-0063-4. View

18.

Aslam S, Buggs J, Melo S, Ermekbaeva A, Rogers E, Shaw R . The Association Between Alcoholic Liver Disease and Alcohol Tax. Am Surg. 2020; 87(1):92-96. DOI: 10.1177/0003134820945223. View

19.

Abul-Husn N, Cheng X, Li A, Xin Y, Schurmann C, Stevis P . A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. N Engl J Med. 2018; 378(12):1096-1106. PMC: 6668033. DOI: 10.1056/NEJMoa1712191. View

20.

Noureddin M, Lam J, Peterson M, Middleton M, Hamilton G, Le T . Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013; 58(6):1930-40. PMC: 4819962. DOI: 10.1002/hep.26455. View